PMID- 34847842
OWN - NLM
STAT- MEDLINE
DCOM- 20220923
LR  - 20221207
IS  - 1875-5402 (Electronic)
IS  - 1386-2073 (Linking)
VI  - 25
IP  - 11
DP  - 2022
TI  - Can We Use mTOR Inhibitors for COVID-19 Therapy?
PG  - 1805-1808
LID - 10.2174/1386207325666211130140923 [doi]
AB  - Infection by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) 
      provokes acute inflammation due to extensive replication of the virus in the 
      epithelial cells of the upper and lower respiratory system. The mammalian target 
      of rapamycin (mTOR) is a l signalling protein with critical functions in cell 
      growth, metabolism, and proliferation. It is known for its regulatory functions 
      in protein synthesis and angiogenesis cascades. The structure of mTOR consists of 
      two distinct complexes (mTORC1 and mTORC2) with diverse functions at different 
      levels of the signalling pathway. By activating mRNA translation, the mTORC1 
      plays a key role in regulating protein synthesis and cellular growth. On the 
      other hand, the functions of mTORC2 are mainly associated with cell proliferation 
      and survival. By using an appropriate inhibitor at the right time, mTOR 
      modulation could provide immunosuppressive opportunities as antirejection 
      regimens in organ transplantation as well as in the treatment of autoimmune 
      diseases and solid tumours. The mTOR also has an important role in the 
      inflammatory process. Inhibitors of mTOR might indeed be promising agents in the 
      treatment of viral infections. They have further been successfully used in 
      patients with severe influenza A/H1N1 pneumonia and acute respiratory failure. 
      The officially accepted mTOR inhibitors that have undergone clinical testing are 
      sirolimus, everolimus, temsirolimus, and tacrolimus. Thus, further studies on 
      mTOR inhibitors for SARS-CoV-2 infection or COVID-19 therapy are well merited.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Aneva, Ina Y
AU  - Aneva IY
AD  - 1Institute of Biodiversity and Ecosystem Research, Bulgarian Academy of Science, 
      Sofia 1113, Bulgaria.
FAU - Habtemariam, Solomon
AU  - Habtemariam S
AD  - Pharmacognosy Research Laboratories and Herbal Analysis Services, School of 
      Science, University of Greenwich, Central Avenue, Chatham-Maritime, Kent ME4 4TB, 
      United Kingdom.
FAU - Banach, Maciej
AU  - Banach M
AD  - Department of Hypertension, Chair of Nephrology and Hypertension, Medical 
      University of Lodz, Lodz, Poland.
AD  - Polish Mother\'s Memorial Hospital Research Institute (PMMHRI), Lodz, Poland.
FAU - Sil, Parames C
AU  - Sil PC
AD  - Division of Molecular Medicine, Bose Institute P-1/12, CIT Scheme VII M, Kolkata 
      700054, India.
FAU - Sarkar, Kasturi
AU  - Sarkar K
AD  - Department of Microbiology, St. Xavier\'s College, Kolkata, India.
FAU - Sahebnasagh, Adeleh
AU  - Sahebnasagh A
AD  - Clinical Research Center, Department of Internal Medicine, North Khorasan 
      University of Medical Sciences, Bojnurd, Iran.
FAU - Kamal, Mohammad Amjad
AU  - Kamal MA
AD  - West China School of Nursing / Institutes for Systems Genetics, Frontiers Science 
      Center for Disease-related Molecular Network, West China Hospital, Sichuan 
      University, Chengdu 610041, Sichuan, China.
AD  - King Fahd Medical Research Center, King Abdulaziz University, P. O. Box 80216, 
      Jeddah 21589, Saudi Arabia.
AD  - Enzymoics; Novel Global Community Educational Foundation, Australia.
FAU - Khayatkashani, Maryam
AU  - Khayatkashani M
AD  - Amol University of Special Modern Technologies, Amol, Iran.
FAU - Kashani, Hamid Reza Khayat
AU  - Kashani HRK
AD  - Department of Neurosurgery, Imam Hossein Hospital, Shahid Beheshti University of 
      Medical Sciences, Tehran, Iran.
LA  - eng
PT  - Journal Article
PL  - United Arab Emirates
TA  - Comb Chem High Throughput Screen
JT  - Combinatorial chemistry & high throughput screening
JID - 9810948
RN  - 0 (MTOR Inhibitors)
RN  - 0 (Multiprotein Complexes)
RN  - 9HW64Q8G6G (Everolimus)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (Mechanistic Target of Rapamycin Complex 1)
RN  - EC 2.7.11.1 (Mechanistic Target of Rapamycin Complex 2)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - W36ZG6FT64 (Sirolimus)
RN  - WM0HAQ4WNM (Tacrolimus)
SB  - IM
MH  - Everolimus
MH  - Humans
MH  - *Influenza A Virus, H1N1 Subtype/metabolism
MH  - MTOR Inhibitors
MH  - Mechanistic Target of Rapamycin Complex 1/metabolism
MH  - Mechanistic Target of Rapamycin Complex 2/metabolism
MH  - Multiprotein Complexes/genetics/metabolism
MH  - SARS-CoV-2
MH  - Sirolimus/pharmacology
MH  - TOR Serine-Threonine Kinases/genetics
MH  - Tacrolimus
MH  - *COVID-19 Drug Treatment
OTO - NOTNLM
OT  - COVID-19
OT  - SARS-CoV-2
OT  - everolimus
OT  - mTOR inhibitors
OT  - rapamycin
OT  - sirolimus
OT  - temsirolimus
EDAT- 2021/12/02 06:00
MHDA- 2022/09/24 06:00
CRDT- 2021/12/01 05:46
PHST- 2021/07/14 00:00 [received]
PHST- 2021/09/27 00:00 [revised]
PHST- 2021/10/08 00:00 [accepted]
PHST- 2021/12/02 06:00 [pubmed]
PHST- 2022/09/24 06:00 [medline]
PHST- 2021/12/01 05:46 [entrez]
AID - CCHTS-EPUB-119140 [pii]
AID - 10.2174/1386207325666211130140923 [doi]
PST - ppublish
SO  - Comb Chem High Throughput Screen. 2022;25(11):1805-1808. doi: 
      10.2174/1386207325666211130140923.